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We used a comprehensive metabolomics approach to study the altered urinary metabolome 
of two mitochondrial myopathy, encephalopathy lactic acidosis and stroke like episodes (MELAS) 
cohorts carrying the m.3243A>G mutation. 
The first cohort were used in an exploratory phase, identifying 36 metabolites that were 
significantly perturbed by the disease. During the second phase, the 36 selected metabolites were 
able to separate a validation cohort of MELAS patients completely from their respective control 
group, suggesting usefulness of these 36 markers as a diagnostic set. Many of the 36 perturbed 
metabolites could be linked to an altered redox state, fatty acid catabolism and one-carbon 
metabolism. However, our evidence indicates that, of all the metabolic perturbations caused by 
MELAS, stalled fatty acid oxidation prevailed as being particularly disturbed.   
The strength of our study was the utilization of five different analytical platforms to generate 
the robust metabolomics data reported here. We show that urine may be a useful source for 
disease-specific metabolomics data, linking, amongst others, altered one-carbon metabolism to 
MELAS. The results reported here are important in our understanding of MELAS and might lead to 
better treatment options for the disease. 
 
Keywords 
















Mitochondrial diseases are one of the most common inborn errors of metabolism, with a 
minimum prevalence of 1:5000 (Gorman et al., 2015; Schaefer et al., 2004). Mitochondrial 
myopathy, encephalopathy, lactic acidosis and stroke like episodes, better known as MELAS (MIM 
540000), is one such a mitochondrial disease and was first described in 1984 as a 
“neurodegenerative disease caused by the decreased ability of cells to produce sufficient energy in 
the form of ATP” (Pavlakis et al., 1984). In 1990, the MELAS phenotype was associated with a specific 
mutation, now known as the m.3243A>G mutation (Goto et al., 1990). This mutation is a point 
mutation on position 3243 of the mitochondrial DNA (mtDNA), where an adenine (A) is substitute d 
with a guanine (G) in the MT-TL 1 gene. The latter gene encodes for a transfer ribonucleic acid 
(tRNA), which recognizes the codons UUA and UUG for the amino acid leucine  in mitochondrial 
translation (Scaglia and Northrop, 2006; Kami et al., 2012). The mutation thus disturbs mitochondrial 
protein synthesis, ultimately affecting Complexes I, III, IV and V of the oxidative phosphorylation 
(OXPHOS) system. Although almost 80% of all MELAS cases are caused by the m.3243A>G mutation, 
other mtDNA mutations have later been associated with the MELAS phenotype, including the 
m.3244G>A, m.3258T>C, m.3271T>C, m.3291T>C and m.8356T>C mutation (Ruiz-Pesini, 2007; 
Scaglia and Northrop, 2006). 
 
Patients diagnosed with MELAS can also present with a wide range of symptoms, varying in 
degree of prevalence and severity. However, in this study, a MELAS phenotype was defined as a 
patient carrying the m.3243A>G mutation AND that had at least one stroke like episode. Although 
late onset MELAS does occur, these patients were not included in this study. Initially, the m.3243A>G 
mutation was specifically associated with MELAS, however, over time various other phenotypes 
have also been linked to this mutation, including maternally inherited diabetes and deafness (MIDD), 
progressive external ophthalmoplegia (PEO) and mitochondrial recessive ataxia syndrome (MIRAS) 















A recent study attempted to identify mechanistic differences between different m.3243A>G 
phenotypes using nuclear magnetic resonance (NMR) spectroscopy. With this single metabolomics 
technique, the authors were able to identify six urinary metabolites (all decreased in the patients, 
compared to the controls) that were able to distinguish MELAS patients from controls (Hall et al., 
2015). The markers included N-methylnicotinamide, hippurate, creatinine, 4-cresyl sulfate, glycolate, 
and a marker with unconfirmed identity, possibly 4-hydroxyphenylacetic acid. Although these 
markers point towards altered phenylalanine and tyrosine metabolism, arginine metabolism 
(creatinine) and a connection to gut microbial metabolism (4-cresyl sulfate and glycolate), the exact 
mechanism(s) for these changes remains elusive. Here we aimed to extend these findings on MELAS 
by investigating the urine metabolome of MELAS patients using a multi-platform metabolomics 
approach. With a larger metabolome coverage, additional metabolites affected in the MELAS 
patients, compared to healthy controls, can potentially be identified. This can potentially provide a 
more extensive and improved biochemical understanding of the metabolic perturbations resulting 
from this specific phenotype. 
 
2. METHODS 
2.1 Patients and Ethics 
Urine samples of two cohorts of genetically confirmed m.3243A>G MELAS patients and healthy 
controls were obtained from the Radboud University Medical Center in Nijmegen, The Netherlands 
and the University of Helsinki, Finland. To ensure group homogeneity, exclusion criteria were applied 
to the original cohorts, namely, 1) controls that received either medication or supplementation at 
the time of sample collection; 2) controls with a medical condition (such as diabetes, hypertension, 
etc.) Characteristics of the patients and controls are summarized in Tables 1 and 2, including data on 















The study complied with all applicable institutional guidelines and terms of the Declaration of 
Helsinki of 1975 (as revised in 2013) for investigation of human participants. Ethical approval was 
obtained from the Health Research Ethics Committee (HREC) of  the North-West University (NWU-
00170-13-S1). All the patients as well as the controls provided written informed consent for their 
urine samples to be used for research purposes. 
 
2.2 Metabolic Profiling 
A multi-platform metabolomics approach, which consisted of targeted as well as untargeted 
techniques, was used to analyze the urine samples of the MELAS patients and healthy controls in 
order to obtain an extensive metabolomics data set. Targeted analyses consisted of liquid 
chromatography tandem-mass spectrometry (LC-MS/MS) while untargeted analyses consisted of gas 
chromatography–mass spectrometry (GC-MS), nuclear magnetic resonance (NMR) spectroscopy and 
liquid chromatography mass spectrometry with ion mobility (LC-IM-MS) — in positive and negative 
ionization mode. The protocols for the metabolomics techniques and sample preparation used are 
discussed in detail in the SI. 
 
 
2.3 Statistical analyses 
Data matrixes obtained from the GC-MS, LC-MS/MS, NMR and the two LC-IM-MS platforms 
were pre-processed individually and were then combined into one single metabolomics data set 
(pre-processing details are given in the SI) . The data were normalized to creatinine, as discussed in 
the SI. The data was then log-transformed before univariate and multivariate statistical analyses. 
Univariate analyses (student t–test and effect size) were performed in Excel 2013 (Microsoft Inc.), 
while the multivariate analyses [principle component analysis (PCA) and heatmaps] were done using 
Matlab (Mathworks, Natick, Ma) and MetaboAnalyst 3.0 (www.metaboanalyst.ca), respectively. A 














thus showing statistical significant and practical differences between the patient group and the 
healthy controls. The covariance and discriminatory power of the important metabolites were 
visualized with PCA, heatmaps and a volcano plot. The identity of the important features were 
determined from matching the spectral information (NMR), retention time, high resolution mass 
and/or fragmentation spectra (MS) to in-house and commercial libraries as well as public databases. 
Confidence levels for each identity were included (Fiehn et al., 2007) as well as the analytical 
platform used to detect the metabolite (Table 3). 
 
3. RESULTS  
3.1 Exploratory phase 
The Nijmegen cohort were utilized for the exploratory phase, i.e. searching for a 
biosignature for MELAS. Univariate measures — student’s t-test (p < 0.05) and effect size (d > 0.8) — 
highlighted 36 metabolites that differed significantly between the MELAS patients and healthy 
controls (Table 3). All but four of the 36 urinary metabolites were increased in the MELAS patients 
(Fig. 1B + C), with only sarcosine, glycerol, hydroxylamine and 6-azathymine being decreased. The 
visualized covariance of these metabolites (Fig. 1A) resulted in separate grouping of the MELAS 
patients and controls (albeit with some overlap). The PCA scores plot show that the MELAS patients 
are more homogenous than the controls – indicating a more defined metabolic profile in comparison 
to the controls. A Venn diagram (Fig. 2) illustrates the contribution of each analytical platform used 
in this study towards the final 36 important metabolites detected. Although a large number of 
features were detected using each analytical platform, only those metabolites that differed 
significantly between the MELAS and control groups and could be identified/partially identified were 
considered — forming the final metabolic fingerprint. 
 
 














The Helsinki cohort were used for the validation phase of this study. After identifying the 36 
metabolites for MELAS using the Nijmegen cohort during the exploratory phase, data on the same 
36 metabolites were extracted from the Helsinki cohort and used for the validation phase. The 
visualized covariance of these metabolites (Fig. 3) showed that the 36 metabolite fingerprint 
strongly separated MELAS patients from controls in a different sample set. 
 
4. DISCUSSION 
We report here a multi-platform metabolomics investigation of the urinary metabolome of 
MELAS patients carrying the m.3243A>G mutation. We show that urine may be a useful source for 
disease-specific metabolomics data. Furthermore, we identified a 36 metabolite fingerprint that 
partially-separated the patients from the controls in two separate cohorts, suggesting usefulness of 
these 36 separate markers as a diagnostic set. 
 
Several of the affected pathways identified by our metabolomics approach was disturbed by 
redox-status (Fig. 4), with increased levels of lactic acid, pyruvic acid, acetoacetic acid and the 
branched chain amino acids (leucine, , isoleucine). These metabolites have previously been linked to 
mitochondrial diseases in various studies, using different mitochondrial disease models ( Esterhuizen 
et al., 2017) and fits with an altered NAD+/NADH ratio, now considered key in the development of 
mitochondrial disease (Khan et al., 2014). Cofactors NADH and FADH2 are formed in the tricarboxylic 
acid (TCA) cycle and serve as electron carriers onto the complexes of the OXPHOS system. When a 
defect in any one of the components of the OXPHOS system occurs, the flow of electrons along this 
chain is hindered. This perturbed flow results in altered levels of oxidized cofactors (NAD+, FADH) to 
reduced cofactors (NADH, FADH2), i.e. a redox imbalance (Brière et al., 2004; Khan et al., 2014; 
Naviaux, 2014; Reinecke et al., 2009; Smeitink et al., 2006), affecting dehydrogenase enzymes.  A 
redox imbalance could explain the altered lactic and pyruvic acid levels detected as lactate 














metabolites. The lactate/pyruvate ratio, an indicator of cytosolic redox state (Munnich et al., 1996) 
was slightly increased in the urine of MELAS patients, compared to the controls, although not 
statistically significant (P=0.2). Furthermore, since branched chain amino acids are ultimately 
metabolized to their respective α-keto acids through the branched-chain α-keto acid dehydrogenase 
complex (BCKDC), altered BCKDC activity, caused by a redox imbalance, could elucidate the 
accumulation of the isoleucine and leucine detected in the MELAS cohort. Another point of interest 
was the ketone body acetoacetic acid, which is converted to 3-hydroxybutyric acid by 3-
hydroxybutyric acid dehydrogenase. Since the activity of this enzyme is also dependent on the redox 
balance, an altered redox balance caused by MELAS could explain the increased levels of acetoacetic 
acid found in our MELAS patient group. Thus our findings suggest that urine reflects the overall 
redox-balance of the body. 
 
Currently receiving a lot of attention in the field of mitochondrial disease research is an intricate 
web of pathways consisting of one-carbon metabolism, the methylation cycle and the trans-
sulfuration pathway. It has been hypothesized that these pathways could be affected in defective 
OXPHOS systems, but it was not until recent studies that this intricate web of pathways was 
positively associated with the disease (Bao et al., 2016; Nikkanen et al., 2016). In addition to a redox 
imbalance, our data is also supportive of alterations in this cluster of pathways, with increased levels 
of, cysteine, trimethylglycine (betaine), taurine, and trimethylamine N-oxide (TMAO) detected (Fig. 
4D and Table 3). Firstly, cysteine is metabolized to taurine through a cofactor-dependent reaction, 
thus influencing the taurine levels detected in the MELAS patients. Secondly, during the methylation 
cycle, homocysteine is converted to methionine through a reaction where choline is converted to 
trimethylglycine (betaine), ultimately producing dimethylglycine. Finally, choline additionally 
produces trimethylamine (TMA), which is further broken down to TMAO and dimethylamine. Thus 














trans-sulfuration pathway and methylation cycle, explaining the altered levels of all these 
metabolites observed in this study. 
 
Another component of the metabolism that seems to be strongly affected by MELAS is fatty acid 
oxidation. We hypothesize that stalled beta-oxidation is responsible for the altered levels of glycerol, 
butyric/valeric acid (short chain fatty acid), caproic/caprylic acid (medium chain fatty acid) , carnitine, 
acetyl-carnitine (C2) and butanoyl-carnitine (C4). The altered levels of isovaleryl-carnitine (C5) and 
propionyl-carnitine (C3) are indicative of altered uneven-chain fatty acid and/or altered amino acid 
catabolism. From the volcano plot (Fig. 1C), some of the most discriminatory (statistically significant) 
metabolites in the MELAS patients can be linked to stalled fatty acid catabolism/beta-oxidation. 
Many carnitine conjugates also increased in the MELAS group, however, the question arose as to 
how free carnitine can be increased as well in the MELAS group while it is used for detoxification and 
hence excreted in elevated levels as conjugates. For this to be possible, increased carnitine 
biosynthesis is needed. However, such a scenario would require one-carbon units in the form of s-
adenosylmethionine for the synthesis of carnitine via trimethyllysine. We thus speculate that due to 
the increased carnitine conjugates excreted in the urine of MELAS patients, one -carbon metabolism 
is affected in an effort to replenish the diminished carnitines. Thus, although many of the effected 
metabolites we report here can be linked to a redox imbalance and one-carbon metabolism, 
methylation and transsulfuration, our results indicate that stalled fatty acid oxidation was severely 
affected in this MELAS cohort.   
 
Other metabolites detected as increased can be linked to different metabolic pathways. 
Increased amino acid catabolism (possibly through the activation of AMPK due to low energy levels) 
is supported by the increased levels of arginine, N2-succinyl-L-glutamic acid 5-semialdehyde, aspartic 
acid, and urea. Even though some of the patients received carnitine (n = 1) and arginine (n = 2) 














amino acid catabolism (Fig. 4B), even when the patients receiving supplementation were excluded 
from the data analysis (data not shown). Altered levels of xanthine is supportive of affected purine 
pathway. Lastly, 2,3-butandiol would normally be associated with high level of alcohol consumption; 
however, this metabolite can also be expected in urine when high level of glucose (as detected in the 
MELAS patients) are present as it is further metabolized by the gut microbes (Elshaghabee et al., 
2016; Venkataraman et al., 2014). Additionally the increased levels of 4-hydroxyvaleric acid could 
also be ascribed to gut microbial metabolism. Since seven of the nine MELAS patients demonstrated 
GI dysmotility, the altered levels of 2,3-butandiol and 4-hydroxyvaleric acid could indeed be due to 
altered gut metabolism on the measured urinary metabolome. 
 
A study in 2015 (Hall et al., 2015) of renal involvement in mitochondrial disease included a 
cohort of 14 patients with the MELAS phenotype; NMR was utilized to identify six potential urinary 
markers (N-methylnicotinamide, hippurate, creatinine, 4-cresyl sulfate, glycolate, and a marker with 
unconfirmed identity, possibly 4-hydroxyphenylacetic acid). In our study, we detected and quantified 
N1-methylnicotinamide, hippurate, creatinine, glycolate, but none of the se markers were 
significantly affected by MELAS (p > 0.05 and d < 0.8) in our cohort. Lastly, our multi-platform 
approach resulted in the detection of 36 metabolites perturbed by MELAS compared to the six 
reported by Hall et al. (2015), whom only used a single analytical platform. 
 
The strength of our study was the utilization of five different analytical platforms to generate the 
robust metabolomics data reported here. Of the five platforms employed, only three (GC-MS, NMR 
and LC-MS/MS) contributed to the majority of our metabolite list as illustrated in Figure 2. Although 
many discriminatory features were detected with untargeted LC-IM-MS, only four metabolites (in 
positive ionization mode) was identified with moderate confidence while none of the discriminatory 
features in negative ionization mode could be identified. Nevertheless, some of the 36 important 














their overlapping coverage of the metabolome, giving more credibility to the metabolite as being 
critical in the disease. One important metabolite were detected by both the NMR and LC-MS/MS 
(alanine) while the overlap between the GC-MS and NMR was two metabolites (lactic acid and 
pyruvic acid). In the light of these findings, we recommend using a multi-platform approach to 
analyze the metabolome in mitochondrial disease studies as the multiple platforms complement 
each other, rather than substitute for each other.  
 
5. CONCLUSION 
We have performed a multi-platform metabolomics investigation on two MELAS cohorts in order 
to better understand the metabolic alterations caused by the disease. To our knowledge , this is the 
first multi-platform metabolomics investigation of the MELAS phenotype. By combining the 
metabolic data sets generated with the multi-platform analytical approach, we were able to cover a 
larger part of the metabolome, which led to the identification of 36 metabolites (during the 
exploratory phase) that differed significantly between the patient and control group, compared to 
the six markers previously reported for the disease (Hall et al., 2015). During the validation phase, 
the 36 selected metabolites were able to separate a validation cohort of two MELAS patients 
completely from their respective control group.  
 
Upon further investigation of our data, most of the disturbed metabolites could be explained by 
a redox imbalance caused by a defective OXPHOS system while stalled fatty acid oxidation prevailed 
as being particularly perturbed in the MELAS phenotype. Furthermore the intricate web of pathways 
consisting of the one-carbon metabolism, methylation cycle and trans-sulfuration pathway — 
previously linked to PEO (Bao et al. 2016; Nikkanen et al., 2016) – can now, with our data, also be 
linked to the MELAS phenotype. Although redox imbalance has previously been associated with 














Smeitink et al., 2006), our data confirms the global impact of mitochondrial disease on the 
metabolism, further contributing to its complexity. 
 
The small number of MELAS patients used in this study (nine MELAS patients for the exploratory 
phase and only two patients for the validation phase) is a limitation of the study. Larger numbers of 
patients would have been preferential, although it was not available to this study. Also, all the 
MELAS patients used in this study had the m.3243A>G mutation – none had any of the numerous 
other MELAS-causing mutations. Thus the biosignature suggested here is specific for this single 
phenotype. Although further research is warranted, this study is the first to follow a comprehensive 
metabolomics analysis approach to identify metabolites altered by the MELAS phenotype. 
Understanding the metabolic alterations of MELAS could further our understanding of the disease 
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A urinary biosignature for mitochondrial myopathy, 
encephalopathy, lactic acidosis and stroke like episodes (MELAS)  
 
 
Table 1: Characteristics of the MELAS patients and healthy controls of the Nijmegen cohort used in 
this study (means ± standard deviation). 
Characteristic Patients Controls 
Total, N 9 29 
Age, y 31.4 ± 11.6 34.8 ± 19.8 
Male 6 10 
Female 3 19 
Creatinine [mmol/L) 7.2 ± 5.2 13.2 ± 7.1 
Osmolality(mOsm/kg)  570.2 ± 279.4 765.6 ± 271.7 
NMDAS Score  44.9 ± 18.7 N/A 
% m.3243A>G 81 ± 0.19 N/A 
   
Symptoms (Number of patients presenting with symptoms)   
Cardiomyopathy 3 (33.3%) N/A 
Epilepsy 7 (77.8%) N/A 
Myopathy 9 (100%) N/A 
Strokes 9 (100%) N/A 
GI dysmotility 7 (77.8%) N/A 
Diabetes 5 (55.6%) N/A 
Renal insufficiency 0 (0%) N/A 
Hearing loss 9 (100%) N/A 
   
Medication (Number of  patients exposed)   
Acetylsalicylic acid 1 (11.1%) N/A 
Angiotensin-converting-enzyme inhibitor (ACE inhibitor) 1 (11.1%) N/A 
Anticoagulant 2 (22.2%) N/A 
Antiepileptic 7 (77.8%) N/A 
Angiotensin Receptor Blockers (ARBs) 1 (11.1%) N/A 
Beta blockers 2 (22.2%) N/A 
Calcium antagonist 1 (11.1%) N/A 
Diuretic 1 (11.1%) N/A 
Insulin 4 (44.4%) N/A 
Laxative 1 (11.1%) N/A 
Statin 1 (11.1%) N/A 














   
Supplements (Number of  patients exposed)   
Arginine 2 (22.2%) N/A 
B12 carnitine 1 (11.1%) N/A 
Carnitine 1 (11.1%) N/A 
Coenzyme Q10 2 (22.2%) N/A 
Folic acid 1 (11.1%) N/A 
Riboflavin 2 (22.2%) N/A 
The m.3243A>G mutation load was determined in urinary epithelial cells as described earlier (de 



































Table 2: Characteristics of the MELAS patients and healthy controls of the Helsinki cohort used in 
this study (means ± standard deviation). 
Characteristic Patients Controls 
Total, N 2 7 
Age, y 54.7 ± 2.2 38.5  ± 13.6 
Creatinine [mmol/L) 7.4 ± 2.4 16.2 ± 2.9 
Osmolality(mOsm/kg)  504.5 ± 187.4 755.0 ± 69.2 
% m.3243A>G  urine 71.5 ± 20.5 N/A 
% m.3243A>G  blood 21.5 ± 9.2 N/A 
   
Symptoms (Number of patients presenting with symptoms)   
Ataxia 1 (50%) N/A 
Cardiomyopathy 2 (100%) N/A 
Depression 2 (100%) N/A 
Diabetes 2 (100%) N/A 
Hearing loss 2 (100%) N/A 
Hyperaldosteronism 1 (50%) N/A 
Myopathy 1 (50%) N/A 
Migraine-type headache 1 (50%) N/A 
Ptosis 1 (50%) N/A 
   
Medication (Number of  patients exposed)     
Acetylsalicylic acid 1 (50%) N/A 
Angiotensin-converting-enzyme inhibitor (ACE inhibitor) 1 (50%) N/A 
Beta blocker 1 (50%) N/A 
Benzodiazepines 2 (100%) N/A 
Insulin 2 (100%) N/A 
Metformin 1 (50%) N/A 
Sulfanylurea derivative 1 (50%) N/A 
   
Supplements (Number of  patients exposed)   
 Calcium 1 (50%) N/A 
Coenzyme Q10 1 (50%) N/A 
Iron 1 (50%) N/A 
Magnesium 2 (100%) N/A 
Omega 2 (100%) N/A 
Vitamin B 1 (50%) N/A 
Vitamin D 1 (50%) N/A 

















Table 3. List of 36 metabolites that differed significantly between MELAS patients and controls in 
the Nijmegen cohort 
 








AMINO ACIDS      
Alanine ↑ 0.001 1.258 1 NMR (LC-MS/MS) 
Arginine ↑ 0.015 0.962 1 LC-MS/MS 
Aspartic acid  ↑ 0.019 0.872 1 LC-MS/MS 
Cysteine ↑ 0.001 1.244 1 LC-MS/MS 
Isoleucine ↑ 0.001 1.050 1 NMR 
Leucine ↑ 0.004 1.007 1 NMR 
Lysine ↑ 0.014 0.895 1 NMR 
N2-Succinyl-L-glutamic acid 
5-semialdehyde 
↑ 0.004 1.052 3 LC-IM-MS (+) 
N-Acetyltryptophan ↑ 0.003 1.118 3 LC-IM-MS (+) 
Proline ↑ 0.004 1.123 1 NMR 
Sarcosine ↓ 0.031 0.853 1 GC-MS 
Taurine ↑ 0.014 0.924 3 GC-MS 
Trimethylglycine (Betaine) ↑ 0.003 1.100 1 NMR 
      
ORGANIC ACIDS      
3-Hydroxybutyric acid ↑ 0.011 0.993 1 GC-MS 
4-Hydroxyglutaric acid ↑ 0.007 1.033 3 GC-MS 
Acetoacetic acid ↑ 0.037 0.810 1 NMR 
Butyric/valeric acid ↑ 0.000 1.107 2 NMR 
Caproic/caprylic acid ↑ 0.000 1.225 2 NMR 
Citric acid ↑ 0.004 1.134 1 NMR 
Glycerol ↓ 0.002 1.183 3 GC-MS 
Lactic acid ↑ 0.004 1.085 1 GC-MS (NMR) 
Pyruvic acid ↑ 0.014 0.987 1 NMR (GC-MS) 
      
CARNITINES      
Carnitine ↑ 0.000 1.068 1 NMR 
C2-Carnitine ↑ 0.000 1.083 1 LC-MS/MS 
C3-Carnitine ↑ 0.000 1.017 1 LC-MS/MS 
C4-Carnitine ↑ 0.002 0.923 1 LC-MS/MS 
C5-Carnitine ↑ 0.000 0.895 1 LC-MS/MS 
      
OTHER      
6-Azathymine ↓ 0.006 0.973 3 GC-MS 
2,3-Butanediol glucoside ↑ 0.002 1.139 3 LC-IM-MS (+) 
Butanal ↑ 0.015 0.834 3 GC-MS 














Hydroxylamine ↓ 0.002 1.081 3 GC-MS 
Resolvin D2 ↑ 0.015 0.877 3 LC-IM-MS (+) 
TMAO ↑ 0.004 0.844 1 NMR 
Urea ↑ 0.024 0.878 1 NMR 
Xanthine ↑ 0.011 0.856 1 NMR 
If a metabolite was detected as significant by more than one analytical platform, the second 
platform is indicated in the table in brackets. ↑ means the metabolite is increased in the MELAS 
patients, relative to the Controls. ↓ means the metabolite is decreased in the MELAS patients, 
















































































Fig 1. Differences between Controls and MELAS patients of the exploration (Nijmegen) cohort 
using the 36 selected variables. A) principal component analysis score (PCA) plot. Sample grouping 
are shown in the PCA with 90 % confidence ellipses; B) heatmap; C) volcano plot. 




































































                                                                                                                                            
 
 
                                                                                                                                                             
 
 






Fig 2. Venn diagram illustrating the contribution of each analytical platform to the detection of the 
36 important metabolites. Five analytical platforms were used to analyze the metabolome of the 
MELAS patients and controls. Although a large number of features were detected using each 
platform, only the metabolites that differed significantly between the MELAS and controls groups 
and that could be identified/partially identified were considered as “important”, thus forming part of 



































Fig 3. Differences between Controls and MELAS patients of the validation (Helsinki) cohort using 
the 36 selected variables. A) principal component analysis score (PCA) - since this cohort only 
contains two MELAS samples, an ellipse could not be drawn for the patient group, although the two 
samples clearly grouped well away from the controls, indicating natural separation. Sample grouping 















































Fig 4. Schematic representation of the altered metabolism detected in the MELAS patients 
compared to healthy controls. A) altered glucose metabolism, B) protein catabolism, C) lipid 
catabolism, D) one-carbon metabolism, methylation cycle and the transsulfuration route. 
Metabolites significantly increased by MELAS (compared to the controls) are indicated in red, those 














increase (d < 1.2); ↑↑↑ = highly increase (d > 1.2) and ↓↓ = moderate decrease (d < 1.2). Cofactor 

















 We used a comprehensive metabolomics approach to study the altered urinary metabolome of 
two MELAS cohorts 
 The first cohort were used in an exploratory phase, identifying 36 metabolites that were 
significantly perturbed by the disease  
 The 36 selected metabolites were able to separate a validation cohort of MELAS patients 
completely from their respective control group 
 Many of the perturbed metabolites could be linked to an altered redox state, fatty acid 
catabolism and one-carbon metabolism 
 We show that urine may be a useful source for disease-specific metabolomics data 
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